Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use

How do the efficacy and safety compare between 100-mg and 300-mg once-monthly extended-release buprenorphine doses for individuals with high-risk opioid use, including fentanyl?In this randomized clinical trial including 436 participants with moderate to severe opioid use disorder, both the 100-mg and 300-mg maintenance doses improved opioid abstinence and were well tolerated without any new safety signals. In post hoc analyses, the 300-mg dose performed better than the 100-mg dose among participants who used fentanyl daily, 14 times or more per week, or both.These findings demonstrate that both 100-mg and 300-mg extended-release buprenorphine doses improved opioid abstinence among patients at high risk; the 300-mg maintenance dose may perform better for individuals with heavy fentanyl use.

Corresponding Author: Robert L. Dobbins, MD, PhD, Research and Development, Indivior Inc, 10710 Midlothian Turnpike, Ste 125, North Chesterfield, VA 23235 (robert.dobbins@indivior.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.